MétaCan
Menu
Back to cohort
Record W4237328149 · doi:10.1016/s0960-9776(13)70002-x

Speakers' Abstracts

2013· article· en· W4237328149 on OpenAlexaff
Aron Goldhirsch, José Baselga, Angelo Di Leo, William D. Foulkes, Jorge S. Reis‐Filho, Karen A. Osborne, Xiaoyong Fu, TF Westbrook, Chad J. Creighton, Susan G. Hilsenbeck, Rachel Schiff

Bibliographic record

VenueThe Breast · 2013
Typearticle
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsMcGill University
Fundersnot available
KeywordsMedicineDermatology

Abstract

fetched live from OpenAlex

The recognition that early breast cancer is a multitude of diseases each requiring a specific systemic therapy has guided the design of the International Breast Cancer Study Group (IBCSG) randomized clinical trials since 1977. Early studies of the Group evaluated chemotherapy and endocrine therapies in subpopulations defined by menopausal status and risk factors. Subsequent trials focused on the timing and duration of chemoendocrine therapies stratified by the endocrine responsiveness of the disease to define personalized treatment strategies. In addition, intensified chemotherapy was tested for patients at very high risk of relapse. The effectiveness of ovarian function suppression/ablation was evaluated in several trials for premenopausal women and the results informed the designs of SOFT and TEXT, which are anticipated to report at the end of this year. Endocrine therapies for postmenopausal women were investigated in several trials using tamoxifen, toremifen or aromatase inhibitors. A risk-adapted model was developed for a personalized approach to patient care. It indicated that for high-risk, higher proliferating breast cancers the efficacy of an aromatase inhibitor is overwhelming when compared to tamoxifen, while the latter may suffice as adjuvant treatment for patients with lower risk breast cancer. The use of anti-HER2 treatments was studied in three consecutive trials within the Breast International Group (BIG) collaboration. These investigated the effectiveness of adjuvant trastuzumab, its duration, and its combination with other anti-HER2 agents. Results from randomized clinical trials are essential for personalizing adjuvant treatments. To define therapies for individual patients we must conduct randomized trials within specific niche populations and perform appropriate subgroup analyses across multiple trials.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.951
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.238
Teacher spread0.230 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueThe BreastSame topicAdvanced Breast Cancer TherapiesFrench-language works237,207